Trang Tony, Petersen John R, Snyder Ned
Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
Clin Chim Acta. 2008 Nov;397(1-2):51-4. doi: 10.1016/j.cca.2008.07.009. Epub 2008 Jul 18.
The APRI and FIB-4 index are markers that have been proposed for the evaluation of hepatic fibrosis in patients co-infected with HIV and HCV.
We retrospectively compared these 2 indices in 81 co-infected patients staged by liver biopsy.
The FIB-4 index was superior to the APRI for the differentiation of mild from significant fibrosis in both predictive values and area under the receiver operator curve (AUROC). The tests were comparable for the differentiation of mild/moderate from advanced fibrosis.
These tests could be used to evaluate co-infected patients for treatment, and exclude those that do not need periodic screening for hepatocellular carcinoma.
APRI和FIB-4指数是用于评估合并感染HIV和HCV患者肝纤维化的标志物。
我们回顾性比较了81例经肝活检分期的合并感染患者的这两个指数。
在预测价值和受试者操作特征曲线下面积(AUROC)方面,FIB-4指数在区分轻度与显著纤维化方面优于APRI。在区分轻度/中度与重度纤维化方面,这两种检测方法相当。
这些检测方法可用于评估合并感染患者是否需要治疗,并排除那些不需要定期筛查肝细胞癌的患者。